• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

二氢嘧啶脱氢酶缺乏症作为致命性5-氟尿嘧啶毒性的一个原因。

Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity.

作者信息

Fidai Shiraz S, Sharma Aarti E, Johnson Daniel N, Segal Jeremy P, Lastra Ricardo R

机构信息

University of Chicago Medicine, Department of Pathology. Chicago, IL, USA.

出版信息

Autops Case Rep. 2018 Nov 30;8(4):e2018049. doi: 10.4322/acr.2018.049. eCollection 2018 Oct-Dec.

DOI:10.4322/acr.2018.049
PMID:30775324
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6360833/
Abstract

5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variety of cancers. Dihydropyrimidine dehydrogenase (DPD) catalyzes the first catabolic step of the 5-FU degradation pathway, converting 80% of 5-FU to its inactive metabolite. Approximately 0.3% of the population demonstrate complete DPD deficiency, translating to extreme toxicity of 5-FU. Here we present a case of a patient who had a fatal outcome after treatment with 5-FU who was found to have an unknown DPD deficiency discovered at autopsy.

摘要

5-氟尿嘧啶（5-FU）与其他细胞毒性药物联合使用，常用于治疗多种癌症。二氢嘧啶脱氢酶（DPD）催化5-FU降解途径的第一步分解代谢，将80%的5-FU转化为其无活性代谢物。约0.3%的人群表现出完全性DPD缺乏，这会导致5-FU产生极端毒性。在此，我们报告一例患者，其在接受5-FU治疗后出现致命结局，尸检时发现存在未知的DPD缺乏。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/0d509c162e4b/autopsy-08-04e2018049-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/fdc9bcd4ced9/autopsy-08-04e2018049-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/7a24f9ad63de/autopsy-08-04e2018049-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/6f5495389b35/autopsy-08-04e2018049-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/0d509c162e4b/autopsy-08-04e2018049-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/fdc9bcd4ced9/autopsy-08-04e2018049-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/7a24f9ad63de/autopsy-08-04e2018049-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/6f5495389b35/autopsy-08-04e2018049-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8c2/6360833/0d509c162e4b/autopsy-08-04e2018049-g04.jpg

相似文献

1
Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity.二氢嘧啶脱氢酶缺乏症作为致命性5-氟尿嘧啶毒性的一个原因。
Autops Case Rep. 2018 Nov 30;8(4):e2018049. doi: 10.4322/acr.2018.049. eCollection 2018 Oct-Dec.
2
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.通过治疗前二氢嘧啶脱氢酶缺乏症筛查预防5-氟尿嘧啶引起的早期严重毒性：多参数方法的评估
Semin Oncol. 2017 Feb;44(1):13-23. doi: 10.1053/j.seminoncol.2017.02.008. Epub 2017 Feb 11.
3
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.三醋酸尿苷（Vistogard）在挽救二氢嘧啶脱氢酶（DPYD）缺乏患者严重5-氟尿嘧啶毒性方面的益处。
Cancer Chemother Pharmacol. 2016 Jul;78(1):151-6. doi: 10.1007/s00280-016-3063-1. Epub 2016 Jun 8.
4
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].[二氢嘧啶脱氢酶（DPD）缺乏症筛查与基于氟嘧啶的化疗保障：法国GPCO-法国国立癌症研究所联盟和RNPGx网络的更新与建议]
Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24.
5
Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.二氢嘧啶脱氢酶在5-氟尿嘧啶对结直肠癌患者毒性副作用中的假定作用。
Oncology. 1998 Sep-Oct;55(5):468-74. doi: 10.1159/000011897.
6
5-Fluorouracil Neurotoxicity in a Patient With Normal Dihydropyrimidine Dehydrogenase Activity.二氢嘧啶脱氢酶活性正常患者的5-氟尿嘧啶神经毒性
Cureus. 2023 Dec 4;15(12):e49898. doi: 10.7759/cureus.49898. eCollection 2023 Dec.
7
The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.二氢嘧啶脱氢酶（DPD）调节在5-氟尿嘧啶药理学中的作用。
Oncology (Williston Park). 1998 Oct;12(10 Suppl 7):23-7.
8
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.二氢嘧啶脱氢酶对5-氟尿嘧啶药物遗传学和药物基因组学的影响。
Pharmacogenomics. 2002 Jul;3(4):485-92. doi: 10.1517/14622416.3.4.485.
9
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.一名患有二氢嘧啶脱氢酶缺乏症的患者出现与5-氟尿嘧啶相关的长期严重神经毒性。
Cancer Invest. 1999;17(3):201-5. doi: 10.3109/07357909909021422.
10
Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.检测二氢嘧啶脱氢酶缺乏症以个体化5-氟尿嘧啶治疗。
Cancers (Basel). 2022 Jun 30;14(13):3207. doi: 10.3390/cancers14133207.

引用本文的文献

1
Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity.肿瘤学中的前药：生物活化及其对治疗效果和毒性的影响。
Int J Mol Sci. 2025 Jan 24;26(3):988. doi: 10.3390/ijms26030988.
2
Focal Neurotoxicity Associated With Topical 5-Fluorouracil.与局部应用5-氟尿嘧啶相关的局灶性神经毒性
Cureus. 2024 Feb 17;16(2):e54365. doi: 10.7759/cureus.54365. eCollection 2024 Feb.
3
New Transcriptomic Biomarkers of 5-Fluorouracil Resistance.5-氟尿嘧啶耐药的新型转录组生物标志物

本文引用的文献

1
New advances in DPYD genotype and risk of severe toxicity under capecitabine.DPYD基因分型与卡培他滨治疗下严重毒性风险的新进展
PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.
2
Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.影响抗癌药物药代动力学的基因分型
Clin Pharmacokinet. 2017 Apr;56(4):317-337. doi: 10.1007/s40262-016-0450-z.
3
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Int J Mol Sci. 2023 Jan 12;24(2):1508. doi: 10.3390/ijms24021508.
4
Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.遗传多态性在药物代谢酶介导的毒性和抗癌药物药代动力学耐药中的作用：药物基因组学方面的综述。
Clin Pharmacokinet. 2022 Nov;61(11):1495-1517. doi: 10.1007/s40262-022-01174-7. Epub 2022 Sep 30.
5
Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series.5-氟尿嘧啶（5-FU）诱导的急性白质脑病的诊断和治疗：单中心病例系列研究的经验教训。
J Egypt Natl Canc Inst. 2022 May 23;34(1):22. doi: 10.1186/s43046-022-00117-4.
6
A narrative review of genetic factors affecting fluoropyrimidine toxicity.影响氟嘧啶毒性的遗传因素的叙述性综述。
Precis Cancer Med. 2021 Dec;4. doi: 10.21037/pcm-21-17. Epub 2021 Dec 30.
7
Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study.5-氟尿嘧啶治疗后发生严重毒性反应患者的二氢嘧啶脱氢酶缺乏症：一项回顾性单中心研究
Ann Gastroenterol. 2021;34(1):68-72. doi: 10.20524/aog.2020.0551. Epub 2020 Oct 12.
8
Overexpression of sortilin is associated with 5-FU resistance and poor prognosis in colorectal cancer.索替林过表达与结直肠癌患者对 5-FU 耐药及预后不良相关。
J Cell Mol Med. 2021 Jan;25(1):47-60. doi: 10.1111/jcmm.15752. Epub 2020 Dec 16.
9
β-Elemene Reverses the Resistance of p53-Deficient Colorectal Cancer Cells to 5-Fluorouracil by Inducing Pro-death Autophagy and Cyclin D3-Dependent Cycle Arrest.β-榄香烯通过诱导促死亡自噬和细胞周期蛋白D3依赖性细胞周期阻滞逆转p53缺陷型结肠癌细胞对5-氟尿嘧啶的耐药性。
Front Bioeng Biotechnol. 2020 May 8;8:378. doi: 10.3389/fbioe.2020.00378. eCollection 2020.
10
and Fluorouracil-Based Chemotherapy: Mini Review and Case Report.以及基于氟尿嘧啶的化疗：综述与病例报告
Pharmaceutics. 2019 May 1;11(5):199. doi: 10.3390/pharmaceutics11050199.
基于二氢嘧啶脱氢酶活性个体化氟嘧啶化疗以提高安全性 - 准备好临床实践了吗？
Cancer Treat Rev. 2016 Nov;50:23-34. doi: 10.1016/j.ctrv.2016.08.002. Epub 2016 Aug 13.
4
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.DPYD 变异 c.1679T>G、c.1236G>A/HapB3 和 c.1601G>A 作为预测氟嘧啶类药物相关严重毒性的指标的临床意义：一项基于个体患者数据的系统评价和荟萃分析。
Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23.
5
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. upfront 基因分型 DPYD*2A 以实现氟尿嘧啶类药物个体化治疗：安全性和成本分析。
J Clin Oncol. 2016 Jan 20;34(3):227-34. doi: 10.1200/JCO.2015.63.1325. Epub 2015 Nov 16.
6
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.二氢嘧啶脱氢酶药物遗传学检测中未被发现的毒性风险。
Int J Mol Sci. 2015 Apr 21;16(4):8884-95. doi: 10.3390/ijms16048884.
7
Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes.转移性头颈部鳞状细胞癌的系统治疗和医学管理：文献回顾及治疗变更建议。
Oral Oncol. 2013 Jun;49(6):482-91. doi: 10.1016/j.oraloncology.2013.01.005. Epub 2013 Feb 13.
8
Molecular profiling for personalized cancer care.分子谱分析用于癌症个体化治疗。
Clin Exp Metastasis. 2012 Oct;29(7):653-5. doi: 10.1007/s10585-012-9483-3. Epub 2012 Jun 8.
9
Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.采用贝叶斯有限采样策略评估 DPYD c.1905+1G>A 突变的癌症患者体内 5-氟尿嘧啶的药代动力学。
Clin Pharmacokinet. 2012 Mar 1;51(3):163-74. doi: 10.1007/BF03257473.
10
Phase II drug metabolizing enzymes.II期药物代谢酶
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Jun;154(2):103-16. doi: 10.5507/bp.2010.017.